Nasus Pharma (NSRX) Life Sciences Virtual Investor Forum summary

Technology and product overview

• Proprietary powder technology enables enhanced intranasal absorption with small, spherical particles for optimal delivery.

• Lead product is a needle-free, compact epinephrine powder for anaphylaxis, offering significant advantages over EpiPen, including longer shelf life and ease of use.

• Technology is being applied to additional molecules, including ondansetron for chemotherapy-induced nausea and two undisclosed candidates in metabolic and cardiovascular spaces.

Clinical development and data

• Lead epinephrine product (NS002) completed a comprehensive phase 2 study, showing faster and higher absorption than EpiPen, with 91% of subjects reaching therapeutic threshold in 5 minutes.

• Product demonstrated comparable Cmax to EpiPen, superior speed of onset (shorter Tmax and T100), and favorable safety profile with only mild, self-resolving local adverse events.

• Pivotal phase 3 study to begin in Q4 2024, with top-line data expected in Q1 2027 and NDA submission targeted for mid-2027.

Market opportunity and competitive landscape

• Anaphylaxis market estimated at $2.5 billion, projected to grow to $4–5 billion due to rising allergy incidence and needle-free product adoption.

• Only about a third of at-risk U.S. patients have an epinephrine prescription, leaving significant room for market expansion.

• Competitors include ARS Pharmaceuticals (liquid intranasal), Aquestive (sublingual), and Orexo (powder), but NS002 claims superior pharmacokinetics and IP position.